Margetuximab, against HER2, with Fc-engineered and subsequently elevated affinity to CD16A, was shown to be well tolerated and highly effective in patients with HER2-overexpressing carcinomas (Bang et al., 2017). Here, ERBB2 is linked to carcinoma.